NATURE: How does melanoma respond to tumor immunity?

Previous studies have shown that the emergence of a wide range of tumor inflammation can be reflected in high levels of immersive T-cells and interferon-γ (IFN) signals, and can improve the response of melanoma patients to checkpoint immunotherapy.
, however, many tumors escape by activating cellular pathways that lead to immunosuppression.
of these mechanisms is produced by pyridine 2,3-dioxygenase 1 (IDO1) enzyme along the dog urea pathway to produce tryptophan metabolites, which are induced by IFN.
However, in melanoma patients, clinical trials using a combination of inhibiting IDO1 and blocking the PD1 pathline did not improve the effectiveness of treatment compared to individual PD1 path-blocking, suggesting that we did not fully understand the role of IDO1 and the degradation of the resulting tryptophan in mRNA translation and cancer progression.
recently, researchers used the RNA map of melanoma cells to investigate the effects of long-term IFN treatment on mRNA translation.
note that the researchers observed the accumulation of cytose downstream of tryptophan codec and their expected stagnation at tryptophan cryptors.
suggests that in the absence of tryptophan, the ucose experience bypasses tryptophan codes.
examining the accumulation of these tryptophan-related cystic bodies -- known to researchers as "W-bumps" -- suggests that they are characterized by CYG frame transfer events.
consistent with this, the reporting system experiment, combined with proteomic and immunopeptide analysis, demonstrated the induction of the transfer of the cystic framework, as well as the generation and presentation of abnormal transficial peptides on the cell surface after IFN gamma treatment.
induced infant T cells from healthy receptors with abnormal peptides, which can induce peptide-specific T cells.
addition, the experimental results show that IDO1-mediated tryptophan depletion induced by IFN gamma has a certain role in the immune identification of melanoma cells by promoting the diversification of the peptide group landscape.
。